Physician profile
Mandy L Shaw
NPI 1972682870
$1,119.37
in general payments reported to CMS, 2019-2025
23 companies · $27.05 in 2025
The $27.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $368 · 2021: $297 · 2022: $94.89 · 2023: $95.30 · 2024: $80.17 · 2025: $27.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $141.84 | 2020-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $141.27 | 2019-2021 | |
| Abbvie INC. | $111.78 | 2021-2024 | Mavyret |
| Lilly USA, LLC | $97.46 | 2019-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $87.07 | 2019-2022 | |
| Pfizer INC. | $82.82 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.58 | 2020-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Alkermes, INC. | $43.64 | 2022 | |
| Eisai INC. | $34.52 | 2021 | |
| Dexcom, INC. | $32.86 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.53 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $27.05 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.91 | 2019-2021 | |
| Mylan Specialty L.P. | $22.40 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $21.24 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $19.03 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.85 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2021 | |
| Novo Nordisk INC | $14.41 | 2019 | |
| Amarin Pharma, INC. | $14.26 | 2020 | |
| Organon LLC | $13.68 | 2022 | |
| Glaxosmithkline, LLC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.